ArticleSmart medicine2023
Near-infrared light-responsive Nitric oxide microcarrier for multimodal tumor therapy.
Article in Smart medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Polydopamine-Integrated Porcine Small Intestine Decellularized Extracellular Matrix Hydrogel Microparticles for Wound Healing.Smart medicine · 2025Article
- Artificial Spidroin Nanogenerator-Based Articulus Wound Dressing.ChemistryOpen · 2025Article
- Black Phosphorus Tagged Responsive Strontium Hydrogel Particles for Bone Defect Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Photothermally Driven Ultrafast Polymerase Chain Reaction: Mechanisms, Nanomaterial Architectures, and System Integration.Research (Washington, D.C.) · 2025Review
- Emerging nitric oxide gas-assisted cancer photothermal treatment.Exploration (Beijing, China) · 2024Review
- Bioinspired Bone Seed 3D-Printed Scaffold via Trapping Black Phosphorus Nanosheet for Bone Regeneration.Small science · 2024Article
- Near-infrared light-responsive Nitric oxide microcarrier for multimodal tumor therapy.Smart medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nitric oxide (NO) has shown great potential in tumor therapy, and the development of a platform for precise and controllable NO release still needs to be explored. Herein, a microfluidic electrospray strategy is proposed for the fabrication of hydrogel microspheres encapsulating NO donors (S-nitrosoglutathione, GSNO) together with black phosphorus (BP) and chemotherapeutic doxorubicin (DOX) as microcarriers for tumor therapy. Based on the excellent photothermal property of BP and thermal sensitivity of GSNO, the microcarriers exhibit a near-infrared light (NIR)-responsive NO release behavior. Besides, the photothermal performance of the microcarriers accelerates the release of DOX. All these contribute to the excellent tumor-killing effect of the microcarriers by combining multiple therapeutic strategies including NO therapy, photothermal therapy, and chemotherapy. Moreover, it was demonstrated that the NIR-responsive NO delivery microcarriers could significantly inhibit tumor growth without apparent side effects in vivo. Therefore, it is believed that the novel NIR-responsive NO microcarriers are promising candidates in clinical tumor therapy applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.